Manufacturing Antibody-Drug Conjugates (ADCs): Extractables In Single-Use Systems

Antibody-drug conjugates (ADCs) are emerging as a powerful class of targeted cancer therapeutics that combine the precision of monoclonal antibodies with the potent cytotoxic effects of small-molecule drugs. This dual-action approach allows ADCs to selectively deliver toxic payloads directly to cancer cells, which enhances treatment efficacy while reducing damage to healthy tissues—a significant improvement over traditional therapies. However, the production of ADCs is highly intricate, involving multiple tightly controlled stages such as antibody generation, payload synthesis, linker attachment, purification, and final formulation. Each step must meet rigorous standards to ensure the safety, quality, and effectiveness of the final product. As the demand for safer and more adaptable manufacturing solutions grows, single-use systems are gaining traction as ideal platforms for ADC production due to their flexibility and ability to handle highly potent compounds.

Explore how single-use technologies can streamline your ADC manufacturing process.